161 research outputs found
Geographic Distribution and Mortality Risk Factors during the Cholera Outbreak in a Rural Region of Haiti, 2010-2011
In 2010 and 2011, Haiti was heavily affected by a large cholera outbreak that spread throughout the country. Although national health structure-based cholera surveillance was rapidly initiated, a substantial number of community cases might have been missed, particularly in remote areas. We conducted a community-based survey in a large rural, mountainous area across four districts of the Nord department including areas with good versus poor accessibility by road, and rapid versus delayed response to the outbreak to document the true cholera burden and assess geographic distribution and risk factors for cholera mortality
TSH-CHECK-1 test: diagnostic accuracy and potential application to initiating treatment for hypothyroidism in patients on anti-tuberculosis drugs.
Thyroid-stimulating hormone (TSH) promotes expression of thyroid hormones which are essential for metabolism, growth, and development. Second-line drugs to treat tuberculosis (TB) can cause hypothyroidism by suppressing thyroid hormone synthesis. Therefore, TSH levels are routinely measured in TB patients receiving second-line drugs, and thyroxin treatment is initiated where indicated. However, standard TSH tests are technically demanding for many low-resource settings where TB is prevalent; a simple and inexpensive test is urgently needed
Prevalence and risk factors of brucellosis among febrile patients attending a community hospital in south western Uganda
Human brucellosis, a chronic disease contracted through contact with animals and consuption of unpasteurized dairy products is underreported in limited-resource countries. This cross-sectional study aimed to determine the prevalence and risk factors of brucellosis among febrile patients attending a community hospital in South western Uganda. A questionnaire that captured socio-demographic, occupational and clinical data was administered. Blood samples were tested for Brucella antibodies using Rose Bengal Plate Test (RBPT) and blood culture with standard aerobic BACTEC bottle was done. Of 235 patients enrolled, prevalence of brucellosis (RBPT or culture confirmed) was 14.9% (95%CI 10.6-20.1) with a culture confrmation in 4.3% of the participants. The factors independently associated with brucellosis were consumption of raw milk (aOR 406.15, 95% CI 47.67-3461.69); history of brucellosis in the family (aOR 9.19, 95% CI 1.98-42.54); and selling hides and skins (aOR 162.56, 95% CI 2.86-9256.31). Hepatomegaly (p < 0.001), splenomegaly (p = 0.018) and low body mass index (p = 0.032) were more common in patients with brucellosis compared to others. Our findings reveal a high prevalence of brucellosis among febrile patients and highlight a need for implementing appropiate tests, public awareness activities and vaccination of animals to control and eliminate the disease
Use of Vibrio cholerae Vaccine in an Outbreak in Guinea
Producción CientíficaThe use of vaccines to prevent and control cholera is currently under debate. Shanchol is one of the two oral cholera vaccines prequalified by the World Health Organization; however, its effectiveness under field conditions and the protection it confers in the first months after administration remain unknown. The main objective of this study was to estimate the short-term effectiveness of two doses of Shanchol used as a part of the integrated response to a cholera outbreak in Africa. METHODS We conducted a matched case-control study in Guinea between May 20 and October 19, 2012. Suspected cholera cases were confirmed by means of a rapid test, and controls were selected among neighbors of the same age and sex as the case patients. The odds of vaccination were compared between case patients and controls in bivariate and adjusted conditional logistic-regression models. Vaccine effectiveness was calculated as (1-odds ratio) × 100. RESULTS Between June 8 and October 19, 2012, we enrolled 40 case patients and 160 controls in the study for the primary analysis. After adjustment for potentially confounding variables, vaccination with two complete doses was associated with significant protection against cholera (effectiveness, 86.6%; 95% confidence interval, 56.7 to 95.8; P=0.001). CONCLUSIONS In this study, Shanchol was effective when used in response to a cholera outbreak in Guinea. This study provides evidence supporting the addition of vaccination as part of the response to an outbreak. It also supports the ongoing efforts to establish a cholera vaccine stockpile for emergency use, which would enhance outbreak prevention and control strategies
Use of a Cholera Rapid Diagnostic Test during a Mass Vaccination Campaign in Response to an Epidemic in Guinea, 2012
During the 2012 cholera outbreak in the Republic of Guinea, the Ministry of Health, supported by Médecins Sans Frontières - Operational Center Geneva, used the oral cholera vaccine Shanchol as a part of the emergency response. The rapid diagnostic test (RDT) Crystal VC, widely used during outbreaks, detects lipopolysaccharide antigens of Vibrio cholerae O1 and O139, both included in Shanchol. In the context of reactive use of a whole-cell cholera vaccine in a region where cholera cases have been reported, it is essential to know what proportion of vaccinated individuals would be reactive to the RDT and for how long after vaccination
Single-dose cholera vaccine in response to an outbreak in Zambia
Producción CientíficaKilled oral cholera vaccines (OCVs) are part of the standard response package to a cholera outbreak, although the two-dose regimen of vaccines that has been prequalified by the World Health Organization (WHO) poses challenges to timely and efficient reactive vaccination campaigns.1 Recent data suggest that the first dose alone provides short-term protection, similar to that of two doses, which may largely dictate the effect of OCVs during epidemic
Recommended from our members
Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda
Background: There are limited data on region-specific drug susceptibility of tuberculosis (TB) in Uganda. We performed resistance testing on specimens collected from treatment-naive patients with pulmonary TB in Southwestern Uganda for first and second line anti-TB drugs. We sought to provide data to guide regional recommendations for empiric TB therapy. Methods: Archived isolates, obtained from patients at Mbarara Regional Referral Hospital from February 2009 to February 2013, were tested for resistance to isoniazid and rifampicin using the MTBDRplus and Xpert MTB/RIF assays. A subset of randomly selected isolates was tested for second line agents, including fluoroquinolones (FQs), aminoglycosides, cyclic peptides, and ethambutol using the MTBDRsl assay. We performed confirmatory testing for FQ resistance using repeated MTBDRsl, the Mycobacteria growth indicator tube (MGIT) assay, and sequencing of the gyrA and gyrB genes. Results: We tested isolates from 190 patients. The cohort had a median age of 33 years (IQR 26-43), 69% (131/190) were male, and the HIV prevalence was 42% (80/190). No isolates (0/190) were rifampicin-resistant and only 1/190 (0.5%) was isoniazid-resistant. Among 92 isolates tested for second-line drug resistance, 71 (77%) had interpretable results, of which none were resistant to aminoglycosides, cyclic peptides or ethambutol. Although 7 (10%) initially tested as resistant to FQs by the MTBDRsl assay, they were confirmed as susceptible by repeat MTBDRsl testing as well as by MGIT and gyrase gene sequencing Conclusion: We found no MDR-TB and no resistance to ethambutol, FQs, or injectable anti-TB drugs in treatment naïve patients with pulmonary TB in Southwestern Uganda. Standard treatment guidelines for susceptible TB should be adequate for most patients with TB in this population. Where possible, molecular susceptibility testing methods should be routinely validated by culture methods
Eff ectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study
Background Oral cholera vaccines represent a new eff ective tool to fi ght cholera and are licensed as two-dose regimens
with 2–4 weeks between doses. Evidence from previous studies suggests that a single dose of oral cholera vaccine
might provide substantial direct protection against cholera. During a cholera outbreak in May, 2015, in Juba, South
Sudan, the Ministry of Health, Médecins Sans Frontières, and partners engaged in the fi rst fi eld deployment of a
single dose of oral cholera vaccine to enhance the outbreak response. We did a vaccine eff ectiveness study in
conjunction with this large public health intervention.
Methods We did a case-cohort study, combining information on the vaccination status and disease outcomes from a
random cohort recruited from throughout the city of Juba with that from all the cases detected. Eligible cases were
those aged 1 year or older on the fi rst day of the vaccination campaign who sought care for diarrhoea at all three
cholera treatment centres and seven rehydration posts throughout Juba. Confi rmed cases were suspected cases who
tested positive to PCR for Vibrio cholerae O1. We estimated the short-term protection (direct and indirect) conferred by
one dose of cholera vaccine (Shanchol, Shantha Biotechnics, Hyderabad, India).
Findings Between Aug 9, 2015, and Sept 29, 2015, we enrolled 87 individuals with suspected cholera, and an 898-person
cohort from throughout Juba. Of the 87 individuals with suspected cholera, 34 were classifi ed as cholera positive,
52 as cholera negative, and one had indeterminate results. Of the 858 cohort members who completed a follow-up
visit, none developed clinical cholera during follow-up. The unadjusted single-dose vaccine eff ectiveness was 80·2%
(95% CI 61·5–100·0) and after adjusting for potential confounders was 87·3% (70·2–100·0).
Interpretation One dose of Shanchol was eff ective in preventing medically attended cholera in this study. These
results support the use of a single-dose strategy in outbreaks in similar epidemiological settings
The Role of Epidemiology in the Introduction of Vi Polysaccharide Typhoid Fever Vaccines in Asia
Despite the availability of at least two licensed typhoid fever
vaccines-injectable sub-unit Vi polysaccharide vaccine and live, oral
Ty21a vaccine-for the last decade, these vaccines have not been widely
introduced in public-health programmes in countries endemic for typhoid
fever. The goal of the multidisciplinary DOMI (Diseases of the Most
Impoverished) typhoid fever programme is to generate policy-relevant
data to support public decision-making regarding the introduction of Vi
polysaccharide typhoid fever immunization programmes in China, Viet
Nam, Pakistan, India, Bangladesh, and Indonesia. Through
epidemiological studies, the DOMI Programme is generating these data
and is offering a model for the accelerated, rational introduction of
new vaccines into health programmes in low-income countries. Practical
and specific examples of the role of epidemiology are described in this
paper. These examples cover: (a) selection of available typhoid fever
vaccines to be introduced in the programme, (b) generation of
policy-relevant data, (c) providing the 'backbone' for the
implementation of other multidisciplinary projects, and (d) generation
of unexpected but useful information relevant for the introduction of
vaccines. Epidemiological studies contribute to all stages of
development of vaccine evaluation and introduction
- …